Guide

Sublingual Semaglutide (ODT) 2026: Price and the Evidence Gap

Sublingual semaglutide is not the budget option. In the only complete ladder we captured it is the most expensive protocol — $165 to $199 a month against $145 to $165 for

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published 2026-04-01Updated 2026-04-01Sources captured 2026-07-26Medically reviewed not yet — why

Direct answer

Sublingual semaglutide is not the budget option. In the only complete ladder we captured it is the most expensive protocol — $165 to $199 a month against $145 to $165 for the injection. STEP-1 and SELECT studied subcutaneous injection, so bioavailability by a sublingual route is not established by them. The approved oral Wegovy tablet is $149 with its own trial programme.

Answer last reviewed: 2026-07-26

Is the sublingual form cheaper than the injection?

No. The assumption is widespread and, on the figures we hold, backwards.

Sublingual against injectable, same provider, same terms
Term	Injectable	Sublingual ODT	Difference
Month-to-month	$165	$199	+$34
3-month	$149	$185	+$36
6-month	$147	$177	+$30
12-month	$145	$165	+$20
Twelve-month total	$1,740	$1,980	+$240

The evidence gap, stated plainly

STEP-1 studied subcutaneous injection. SELECT studied subcutaneous injection. Absorption by a sublingual route is a different pharmacokinetic question and is not answered by either trial.

Semaglutide's oral bioavailability is low — the approved oral tablet solves that with an absorption enhancer and a dosing protocol, which is why it exists as a separate approved product rather than as the same drug taken differently. A compounded sublingual preparation is not that product and has no equivalent programme behind it.

This is a convenience format for people who do not want injections. It is not established as equivalent to the injection, and we will not present it as one.

What is the honest case for it?

Needle avoidance is a real reason. A treatment you will actually take beats one you will not.
No cold-chain handling at the point of use.
It is dose-flexible in the same way a compounded vial is.

What it is not is cheaper, and it is not the approved oral route.

What about the approved pill?

Needle-free routes compared
Route	Monthly	Trial result	FDA-approved?
Oral Wegovy tablet	$149	15.1%	Yes
Foundayo (orforglipron)	$149	12.4%	Yes
Compounded sublingual semaglutide	$165–$199	—	No

Both approved pills cost less than the compounded sublingual and carry their own trial programmes. If a needle-free route is the requirement, that comparison is the one that matters.

What twelve months costs: flat against dose-tieredFollowing the label's titration schedule, 2.5 mg to a maintenance dose

Show this figure as a table

What twelve months costs: flat against dose-tiered: the same data as a tableFollowing the label's titration schedule, 2.5 mg to a maintenance dose

What twelve months costs: flat against dose-tiered: the same data as a table
Programme	Twelve-month total	Effective monthly
Flat, captured	$2,232	$186 average
Flat month-to-month, captured	$2,580	$215 average
Dose-tiered, typical	$2,568	$214 average
Brand Zepbound, captured	$4,788	$399 average

The dose-tiered line uses a typical published escalation pattern; the flat and brand lines are figures we captured at source. A programme advertising $129 finishes the year above one advertising $186. That crossover is the argument this whole site is built on. How we record price structure.

What is the salt-form question?

Semaglutide sodium and semaglutide acetate are not the same active ingredient as the base form in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. Ask for the exact salt form and concentration in writing. Tirzepatide has no equivalent question.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Every provider against the six testsComputed from the dataset on 2026-07-26 · 30 providers evaluated

Every provider against the six tests
Provider	Captured at source	Publishes a maintenance-dose price	One published structure	Names its fulfilling pharmacy	Answered all four disclosure questions	No figure we had to withdraw	Score
NexLife	Yes	Yes	Yes	Yes	Yes	Yes	6 of 6
Mochi Health	Yes	Yes	Yes	—	—	Yes	4 of 6
Fifty 410	Yes	—	Yes	—	—	Yes	3 of 6
LillyDirect	Yes	—	Yes	—	—	Yes	3 of 6
Trimi	Yes	—	Yes	—	—	Yes	3 of 6
Calibrate	—	—	Yes	—	—	Yes	2 of 6
Enhance.MD	—	—	Yes	—	—	Yes	2 of 6
Form Health	—	—	Yes	—	—	Yes	2 of 6

Each test comes from a case in our casebook, where a published figure failed a check. The table is generated from the records, not written.

The result

NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.

These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Nothing here is a dosing instruction: the schedules described come from approved labelling, and your prescriber sets your regimen.

Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information

Tirzepatide dosing, as the FDA label sets it out
Step	What the label says	Status
Starting dosage	2.5 mg once weekly for 4 weeks	Initiation only — not approved as a maintenance dosage Verified
First increase	To 5 mg once weekly after 4 weeks	Recommended maintenance dosage Verified
Further increases	In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response	A minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mg	Available strengths used during titration	Titration steps, not recommended maintenance dosages Verified
10 mg	Once weekly	Recommended maintenance dosage Verified
15 mg	Once weekly	Recommended maintenance dosage and the maximum Verified
Above 15 mg	No approved dosage exists	Verified Verified

Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.

Why 'cheapest' needs a definition attached

Why 'cheapest' needs a definition attached
Program type	What it covers	Comparable with
Starter program	Introductory period, often lower doses	Other starter programs only
Ongoing program	Standard continuing supply	Other ongoing programs only
Maintenance program	Post-titration supply, often a fixed dose	Other maintenance programs only
Prepaid term	Several months paid upfront	Monthly plans only after conversion
Month-to-month	Cancellable each cycle	Other month-to-month plans only
Microdose program	Sub-therapeutic dosing outside trial evidence	Other microdose programs only

Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Frequently asked questions

Is sublingual semaglutide as effective as the injection?

Not established. STEP-1 and SELECT studied subcutaneous injection; absorption by a sublingual route is a different question those trials do not answer.

Is sublingual semaglutide cheaper?

No. On the ladder we captured it is the most expensive protocol — $1,980 over twelve months against $1,740 for the injection.

What is the cheapest needle-free option?

The approved oral Wegovy tablet at $149, which also has its own trial programme reporting 15.1%.

Provider ranking methodologyCore & Trust
GLP-1 total cost calculatorTools
Download the pricing recordsData
Cheapest FDA-Approved vs Compounded GLP-1 OptionsJournal
Injectable vs Oral GLP-1 MedicationsComparisons
Oral Tirzepatide and Sublingual Products: What Evidence Exists?Pillar / Money
Provider and Study Source LedgerData
Open GLP-1 Data and Evidence LibraryData
GLP-1 Tirzepatide Ranked: Evidence, Prices, Providers & ToolsCore & Trust
Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Ranked. “Sublingual Semaglutide (ODT) 2026: Price and the Evidence Gap.” S.J Partners LLC, 2026-07-26. https://glp1tirzepatideranked.com/compounded-semaglutide-odt-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.